| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
459 |
426 |
$21K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
37 |
37 |
$12K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
142 |
132 |
$6K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
53 |
49 |
$4K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
42 |
35 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
33 |
33 |
$3K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
34 |
32 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
117 |
116 |
$2K |
| 87581 |
|
40 |
40 |
$2K |
| 87486 |
|
40 |
40 |
$2K |
| 90686 |
|
106 |
88 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
75 |
74 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
20 |
20 |
$1K |
| 90744 |
|
93 |
85 |
$1K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
17 |
16 |
$1K |
| 99000 |
|
50 |
49 |
$1K |
| 90633 |
|
57 |
49 |
$945.01 |
| 90713 |
|
50 |
47 |
$831.35 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
32 |
31 |
$813.80 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
20 |
20 |
$479.95 |
| 90716 |
|
22 |
21 |
$364.31 |
| 90651 |
|
18 |
17 |
$300.78 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
19 |
18 |
$0.00 |